In the pharmaceutical industry, value is being destroyed through longer product development times. Given that patent lives are (normally) fixed at 20 years, the double hit of increasing time to market
The sample is drawn from the Industrial R&D Investment Scoreboard published by the IRI/JRC, which tracks the world’s top 1000 firms by R&D spending. Chinese and EU-based pharmaceutical companies form
